 | • レポートコード：MRC2103C090 • 出版社/出版日：Mordor Intelligence / 2021年2月25日 • レポート形態：英文、PDF、119ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料では、世界のアルツハイマー病診断・治療市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療別（コリンエステラーゼ阻害剤、NMDA受容体拮抗薬、その他）分析、診断別（脳イメージング、アルツハイマー病用CFS検査）分析、地域別分析、競争状況、市場機会/将来の見通しなどを掲載しています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のアルツハイマー病診断・治療市場規模：治療別（コリンエステラーゼ阻害剤、NMDA受容体拮抗薬、その他） ・世界のアルツハイマー病診断・治療市場規模：診断別（脳イメージング、アルツハイマー病用CFS検査） ・世界のアルツハイマー病診断・治療市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Alzheimer’s disease diagnostics and therapeutics market are estimated to be valued at USD 6,632.82 million in 2020 and is expected to reach approximately USD 9,073 million in 2026, registering a CAGR of nearly 5.36% during the forecast period. According to the study titled, “Alzheimer’s and Parkinson’s diseases predict different COVID-19 outcomes, a UK Biobank study”, published in November 2020, exhibited that patients suffering from dementia are at the highest risk of mortality from COVID-19. Hence, this is expected to create new opportunities for novel treatment and diagnosis in the market studied.
The key factors propelling the growth of this market are the increasing prevalence of chronic diseases like dementia, increasing pipeline drug development, investment in biomarkers for drug development, and increasing sophisticated diagnostics for early detection. According to the World Alzheimer Report, in 2019, around 50 million people worldwide were reported to be suffering from Alzheimer’s and related dementia, this number is further expected to reach 152 million by the year 2050.
Extensive research studies being conducted related to Alzheimer’s Disease are further accelerating the market growth. For instance, in October 2020, ImmunoBrain Checkpoint Inc. was funded USD 1,000,000 by Alzheimer’s Association to aid Phase 1 clinical trial for “IBC-Ab002” in the treatment of Alzheimer’s. Hence, this is expected to accelerate the market growth. Also, as per the data of the National Institute of Health reported that in July of 2019, there were 132 agents in clinical trials for AD. Twenty-eight agents are in 42 phase 3 trials; 74 agents are in 83 phase 2 trials, and 30 agents are in 31 phase 1 trial. There is an increasing number of agents in each phase, compared with that in the 2018 pipeline. Hence, the increasing number of clinical studies for diagnosis and treatment of Alzheimer’s is expected to drive the market growth.
However, high failure rates of clinical studies related to diagnosis and treatment of Alzheimer’s are expected to hinder the market growth.
Key Market Trends
Cholinesterase Inhibitors are Expected to Hold the Highest Market Share in the Therapeutics Segment
Cholinesterase inhibitors are believed to have the largest market size, and they are expected to witness a high CAGR, during the forecast period. During this pandemic situation, cholinesterase is being studied extensively for its safety, efficacy, and side effects in Alzheimer’s patients with COVID-19 infection. As per the study titled, “Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies”, published in June 2020, the cholinergic anti-inflammatory pathway was observed to be a viable target to control inflammation and prevention of cytokine storm post detection of COVID-19 virus infection in Alzheimer’s patients and acetylcholinesterase inhibitors can potentially be administered as an adjunctive therapy.
Cholinesterase inhibitors can slightly delay the loss of brain function in people who have mild to moderate Alzheimer’s disease. Cholinesterase inhibitors are prescribed to treat symptoms related to memory, thinking, language, judgment, and other thought processes. Some of the drugs approved by the United States Food & Drug Administration are Aricept, Exelon, Razadyne indicated against mild to moderate Alzheimer’s.
Furthermore, companies are investing in the development of new drugs. For instance, in January 2020, Corium Internnatonal Inc. filed New Drug Application (NDA) for ADLARITY (donepezil transdermal system) indicated against treatment for Alzeihmer’s disease. Hence, owing to the developments, the cholinesterase inhibitor drugs market is expected to grow during the forecast period.
North America Dominates the Market and is Expected to do Same in the Forecast Period
North America currently dominates the market for Alzheimer’s disease diagnostics and therapeutics, and it is expected to continue its stronghold for a few more years. The United States holds the largest share of the global Alzheimer’s disease diagnostics and therapeutics market. However, there have been many reports of neurologic complications associated with COVID-19 as well. The COVID-19 pandemic has also caused drastic changes to Alzheimer’s patients’ normal routine with social distancing and lockdowns in place in the United States. Understandably, many Alzheimer’s patients have experienced a negative impact on their mental health.
The rising geriatric population is one of the key factors responsible for the market growth in this country, as older populations are at higher risk of acquiring the disease. As per the data of the United States Census Bureau, in 2019 about 54 million Americans are aged 65 years and above. Furthermore, according to the Alzheimer’s Association, more than 5.8 million Americans suffer from Alzheimer’s disease, as of 2020. Hence, the rising geriatric population coupled with the rising burden of disease is expected to boost the demand of diagnostics and treatment in this country.
The United States is considered to be the global leader in Alzheimer’s disease intervention and management. According to the Alzheimer’s Association, the total healthcare expenditure on patients with dementia was estimated to be USD 357,297 in 2019. Hence, overall the market is expected to register a healthy CAGR over the forecast period.
Furthermore, the increasing number of research studies related to diagnosis and management of Alzheimer’s Disease is expected to drive the market growth. According to the National Clinical Trials Registry (NCT), in the United States, currently, there are about 144 active clinical trials under development for Alzheimer’s disease across different phases. Moreover, due to COVID-19 outbreak in the country, the number of clinical trials is expected to increase at a slow pace, due to the lack of resources and patient’s availability.
Competitive Landscape
The Alzheimer’s disease diagnostics and therapeutics market is moderately competitive and consists of several major players. With technological advancements and product innovation, mid-size to smaller companies are increasing their market presence, by introducing new technologies with better results. Companies, like F. Hoffmann-La Roche, Novartis AG, Merck & Co., Pfizer Inc., and Eli Lily & Co., among others, hold a substantial market share in the Alzheimer’s disease diagnostics and therapeutics market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Use of Biomarkers in Diagnosis and Drug Development
4.2.2 Large Number of Drugs in Pipeline
4.2.3 Emerging Novel Diagnostic Technologies
4.3 Market Restraints
4.3.1 High Failure Rates of Late-stage Drugs
4.3.2 Lack of Surrogate Markers and Challenges in Early Diagnosis
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Product
5.1.1 By Therapeutics
5.1.1.1 Cholinesterase Inhibitors
5.1.1.2 NMDA Receptor Antagonists
5.1.1.3 Other Therapeutics
5.1.2 By Diagnostics
5.1.2.1 Brain Imaging
5.1.2.2 CFS Test for Alzheimer’s Disease
5.2 Geography
5.2.1 North America
5.2.1.1 United States (By Product)
5.2.1.2 Canada (By Product)
5.2.1.3 Mexico (By Product)
5.2.2 Europe
5.2.2.1 Germany (By Product)
5.2.2.2 United Kingdom (By Product)
5.2.2.3 France (By Product)
5.2.2.4 Italy (By Product)
5.2.2.5 Spain (By Product)
5.2.2.6 Rest of Europe (By Product)
5.2.3 Asia-Pacific
5.2.3.1 China (By Product)
5.2.3.2 Japan (By Product)
5.2.3.3 India (By Product)
5.2.3.4 Australia (By Product)
5.2.3.5 South Korea (By Product)
5.2.3.6 Rest of Asia-Pacific (By Product)
5.2.4 Middle East and Africa
5.2.4.1 GCC (By Product)
5.2.4.2 South Africa (By Product)
5.2.4.3 Rest of Middle East and Africa (By Product)
5.2.5 South America
5.2.5.1 Brazil (By Product)
5.2.5.2 Argentina (By Product)
5.2.5.3 Rest of South America (By Product)
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 F. Hoffmann-La Roche
6.1.2 Novartis AG
6.1.3 Merck & Co. Inc.
6.1.4 Pfizer Inc.
6.1.5 Eisai Co. Ltd
6.1.6 Biogen Inc
6.1.7 Johnson & Johnson
6.1.8 Eli Lilly & Company
6.1.9 Lupin Limited
6.1.10 Abbott Laboratories (Allergna PLc)
6.1.11 Siemens Healthineers
6.1.12 Biogen Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS